Introduction {#S1}
============

Melanoma is an important clinical problem, with an estimated 76,250 new cases and 9,180 deaths in 2012 ([@R30]). The clinical behavior of melanoma can be unpredictable, making prognostic predictions difficult in individual patients. While tumor thickness consistently emerges as the single most significant prognostic factor determining survival, and while ulceration increases the risk of death within a given thickness range, additional factors are required to refine the prognostic assessment of melanoma patients. Beyond histological factors that are reliably associated with decreased survival, molecular markers represent the next frontier in the evaluation of melanoma outcome. Despite the identification of numerous putative molecular prognostic factors, no prognostic biomarkers are routinely used in the evaluation of melanoma patients ([@R15]). In addition, few biomarkers have been shown to retain prognostic impact, when measured on more than one platform (i.e., measurements at the DNA *versus* RNA *versus* protein level).

Recent studies performed by our group identified a previously unknown role for the pleckstrin homology domain-interacting protein (PHIP) in melanoma progression ([@R29]). *PHIP* was identified as the top gene overexpressed in metastatic *versus* primary melanomas by gene expression profiling analysis ([@R18]). shRNA-mediated suppression of *PHIP* resulted in significant suppression of melanoma cell invasion and metastatic potential in both murine and melanoma cell lines. High levels of PHIP expression were associated with significantly reduced survival in both mouse models and human tissues. Specifically, high PHIP expression (as determined by immunohistochemical analysis) was independently predictive of DMFS and DSS. In this study, we analyze the role of *PHIP* copy number for its prognostic significance in primary cutaneous melanoma and explore the linkage between PHIP levels and ulceration development in melanoma.

Results {#S2}
=======

Given the recent demonstration of a significant prognostic role for PHIP protein expression and the presence of elevated *PHIP* copy number in melanoma ([@R29]), we aimed to determine the prognostic impact of *PHIP* copy number in primary cutaneous melanoma. *PHIP* copy number was analyzed using FISH on a TMA cohort of 238 specimens, with known immunohistochemical analysis of PHIP protein expression, by an observer blinded to patient outcomes. Overall, 22% of the cohort possessed a mean copy number of 3 or greater. See [Figure 1a](#F1){ref-type="fig"} for representative examples of low *versus* high *PHIP* copy number. As the ratio of *PHIP* and probes representing the centromere of chromosome 6 in almost all of the cases was close to 1.0 ([Table S1](#SD1){ref-type="supplementary-material"}), the primary attribute assessed was percent of cells expressing 3 or more copies of the *PHIP* gene, in which there was a range from 0-87%, with a mean of 33.4%. There was a significant correlation between *PHIP* copy number and level of expression of the PHIP protein (*P* \< 0.0001, [Figure S1](#SD1){ref-type="supplementary-material"}).

Initially, we analyzed the relationship between *PHIP* copy number and melanoma outcome using univariate analysis. High *PHIP* copy number was associated with decreased melanoma survival, when DMFS (*P* = 0.01 by log-rank test) and DSS (*P*= 0.009 by log-rank test) were assessed using Kaplan-Meier analysis ([Figure 1b and 1c](#F1){ref-type="fig"}). In addition, there was a significantly increased risk of distant metastasis or death due to melanoma with the presence of high *PHIP* FISH scores. 45.4% of patients with high copy number had distant metastasis, when compared to 25.5% with low copy number (Fisher's exact test, *P* = 0.015). 42.2% of patients with high copy number died of metastatic melanoma, when compared to 17.7% of patients with low copy number (Fisher's exact test, *P* \< 0.002).

Next, we examined the relationship between *PHIP* copy number and survival using multivariate Cox regression analysis. High *PHIP* FISH scores were significantly predictive of reduced DMFS (*P* = 0.03, [Table 1](#T1){ref-type="table"}) and DSS (*P* = 0.027, [Table 2](#T2){ref-type="table"}) in multivariate models that included tumor thickness, ulceration, age, gender, and tumor site. Thus, *PHIP* copy number was independently predictive of survival associated with melanoma, similar to the results obtained for PHIP protein expression ([@R29]).

Recently, high PHIP immunohistochemical scores were shown to correlate with ulceration status ([@R29]). We aimed to confirm this relationship at the DNA level. High *PHIP* copy number was significantly associated with ulceration status when analyzed by univariate logistic regression analysis (*P*=0.004). In addition, high *PHIP* copy number was associated with a significantly increased risk of developing ulceration. Thus, ulceration was present in 45.5% of cases with high *PHIP* copy number, when compared with 28.8% of cases with low *PHIP* copy number (*P* = 0.013, Fisher's exact test).

Previously, we reported that ulceration was associated with increased tumor vascularity in the primary tumor, when assessed morphologically ([@R20]). Elevated tumor vascularity (as determined by melanomas with prominent *versus* all lower degrees of vascularity) was significantly associated with ulceration status. Ulceration was present in 60.3% of the cases with prominent tumor vascularity, when compared with 22.2% of cases with lower degrees of tumor vascularity (*P* \< 0.0001, Fisher's exact test). This served to confirm the previously reported results in this tissue microarray cohort. We then explored the combined impact of high *PHIP* copy number and elevated tumor vascularity on the development of ulceration. Ulceration was present in 20.2% of melanomas with both low *PHIP* copy number and low tumor vascularity. This increased to 38.8% of cases ulcerated with either prognostic factor elevated, and to 72.2% of melanomas ulcerated, when both factors were elevated (*P* \< 0.0001, Chi-square test of percentage differences).

We then assessed the relationship between *PHIP* copy number and ulceration status, using multivariate logistic regression analysis. Presence of ulceration in melanoma is also known to increase both with increasing tumor thickness and with increasing mitotic rate ([@R4]; [@R31]). A multivariate logistic regression analysis was performed, including low *versus* high *PHIP* copy number, low *versus* high tumor vascularity, tumor thickness, and mitotic rate. All four factors were significantly predictive of the incidence of ulceration ([Table 3](#T3){ref-type="table"}). Thus, *PHIP* FISH scores were independently predictive of ulceration status, even with the inclusion of these other factors (*P* = 0.04).

Next, we explored cellular pathways regulated by PHIP expression potentially relevant to the development of ulceration. Targeted suppression of PHIP (using an anti-*PHIP* shRNA) in C8161.9 human melanoma cells (with elevated *PHIP* copy number) was previously shown to significantly suppress melanoma cell invasiveness and metastatic potential ([@R29]). Given that PHIP functions in the IGF1R pathway that is important in regulating glucose metabolism, we assessed whether suppression of PHIP activity resulted in altered glycolytic activity of melanoma cells. C8161.9 cells expressing the anti-*PHIP* shRNA produced significantly lower amounts of lactate than control cells expressing a shRNA targeting luciferase (anti-*luc* shRNA) ([Figure 2a](#F2){ref-type="fig"}). This was associated with decreased expression of LDH5, the most efficient isoenzyme of lactate dehydrogenase, which catalyzes the conversion of pyruvate to lactate in the final step of glycolysis ([Figure 2b](#F2){ref-type="fig"}). In addition, culturing anti-*PHIP* shRNA-expressing cells in the presence of methylpyruvate, which bypasses glycolysis and directly enters the Krebs cycle, resulted in significantly increased invasion ([Figure 2c](#F2){ref-type="fig"}). Thus, the proinvasive role of PHIP in melanoma is mediated, at least in part, by activating the glycolytic pathway. Moreover, C8161.9 melanoma cells with reduced PHIP expression produced lower levels of VEGF, as determined by an ELISA assay of human VEGF secretion ([Figure 2d](#F2){ref-type="fig"}). As VEGF expression is controlled by HIF1A ([@R14]), melanoma cells with suppressed PHIP expression were also shown to express lower levels of HIF1A by Western analysis ([Figure 2b](#F2){ref-type="fig"}).

Finally, we assessed the effects of suppression of PHIP on the angiogenic potential of human melanoma cells *in vivo*. C8161.9 melanoma cells were inoculated subcutaneously into nude mice, and the resultant tumors examined for microvessel density using immunofluorescence of CD31 positivity. While there was no significant difference in the tumor volume between the two groups (data not shown), tumors in the anti-*PHIP* shRNA-expressing group ([Figure 3a](#F3){ref-type="fig"}, right panel) exhibited large areas of necrosis when compared with the control group ([Figure 3a](#F3){ref-type="fig"}, left panel). Analysis of CD31 expression revealed that the control tumors were characterized by large, abnormal blood vessels and hemorrhage, apparent from autofluorescence of erythrocytes and lipofuscin ([@R5]) ([Figure 3b and 3c](#F3){ref-type="fig"}, left panels). By contrast, the vessels in the anti-*PHIP* shRNA-expressing tumors were smaller, with little or no hemorrhage evident ([Figure 3b and 3c](#F3){ref-type="fig"}, right panels). Finally, the anti-*PHIP* shRNA-expressing tumors had significantly reduced microvessel density when compared with the control tumors (*P* \< 0.02 as assessed both by a T test and by a two-sample randomization test, [Figure 3d](#F3){ref-type="fig"}). Thus, increasing PHIP expression in human melanoma cells promotes angiogenic potential.

Discussion {#S3}
==========

In this manuscript, we describe a previously unreported role for *PHIP* copy number in the prognosis associated with melanoma. *PHIP* FISH scores were predictive of a significantly increased risk of both distant metastasis and death due to melanoma, and were independently predictive of DMFS and DSS. In addition, elevated *PHIP* FISH scores were associated with a higher incidence of ulceration and were independently predictive of ulceration status. The combined impact of *PHIP* copy number and tumor vascularity was additive, as cases with high levels of both factors had a significantly higher incidence of ulceration than cases with low levels of either or both factors. Finally, C8161.9 human melanoma cells with suppressed PHIP expression exhibited reduced glycolytic activity and angiogenic potential.

These results provide further support for the role of PHIP as a molecular prognostic marker for melanoma, as initially described using immunohistochemical analysis of PHIP expression. High PHIP protein expression was associated with a significantly increased risk of distant metastasis and death due to melanoma, and was independently predictive of DMFS and DSS ([@R29]). Our analysis of *PHIP* copy number parallels the results obtained in human and murine melanoma cell lines, in which suppressed PHIP expression resulted in significantly reduced metastatic potential and increased survival in xenograft models.

To date, few markers have been shown to provide significant prognostic impact in melanoma when assessed on more than one platform. For example, SPP1 expression has been shown to have independent prognostic significance when assessed at the RNA and protein levels ([@R26]; [@R9]). Our studies have demonstrated a significant prognostic role for PHIP at both the DNA and protein levels. Although the ratio of *PHIP* to chromosome 6 centromeric probe was close to 1.0 in the great majority of cases examined, changes in *PHIP* copy number, ranging from euploidy to 3 or greater copies, were highly correlated with increased PHIP expression. Additional studies of PHIP levels will be required in distinct cohorts in order to further validate its prognostic role.

Beyond an independent impact on survival, these studies confirmed a significant and independent relationship between PHIP levels and ulceration status. In addition, *PHIP* copy number combined dramatically with tumor vascularity to increase the incidence of ulceration in primary melanoma specimens. Ulceration is an important prognostic factor that has been incorporated into the AJCC staging classification for melanoma for over a decade ([@R2], [@R3]). More recently, ulceration has been suggested as a potential predictive marker of benefit to adjuvant interferon alpha therapy ([@R25]; [@R10]). However, the biologic basis for the development of ulceration is poorly understood.

Increasing incidence of ulceration in melanoma is associated with increasing tumor thickness, mitotic rate, and tumor vascularity ([@R4]; [@R31]). In addition, gene expression profiling studies have identified a gene signature that correlates with ulceration ([@R35]). However, the specific cellular pathways and mechanisms by which ulceration develops are unclear. The linkage between PHIP levels and ulceration implies a role for the IGF1R pathway in ulceration, given PHIP's involvement in this signal transduction pathway. In addition, our studies in human melanoma cells demonstrating that downregulation of PHIP expression results in significantly reduced glycolytic activity, VEGF secretion, and microvessel density provide mechanistic insights, identifying glucose metabolism and tumor angiogenesis as pathways by which ulceration may develop in melanoma.

Tumor cell growth is promoted by increased glucose consumption, a phenomenon known as the Warburg effect ([@R33]). The importance of glycolysis to melanoma progression has been amply reported in melanoma cell lines ([@R16], [@R17]; [@R1]) and is demonstrated clinically by the utility of PET scanning in the radiologic assessment of melanoma both during initial staging ([@R28]; [@R12]) and in response to targeted therapy ([@R24]). Glycolysis in tumor cells is driven by AKT ([@R11]), and PHIP is a potent activator of AKT in melanoma ([@R29]). Moreover, increased glucose metabolism can itself drive tumor angiogenesis, invasion, and metastasis ([@R23]; [@R32]). Thus, our studies on PHIP in melanoma describe a previously unreported link between PHIP, the Warburg effect, tumor angiogenesis, and ulceration development. As PHIP is activated through increased copy number in a subset of melanomas, additional markers of ulceration will need to be identified in melanomas without PHIP activation. However, the mechanistic analyses provided here should facilitate the identification of these additional markers in distinct molecular subsets of melanoma patients.

Finally, our investigation of PHIP in melanoma tissues and cell lines suggests an intriguing link between ulceration and LDH levels. These results imply that a common tumor-promoting pathway (i.e., IGF1R), resulting in increased glycolysis, may underlie the biologic basis of two prominent prognostic markers incorporated into the AJCC staging classification, one that refines the prognosis of localized melanoma, the other the prognosis of disseminated melanoma. Elevated LDH5 expression in primary melanoma has been previously shown to be associated with reduced survival on univariate analysis, but was not independently predictive of melanoma outcome ([@R36]). Furthermore, LDH activity has been correlated to HIF1A expression and angiogenic potential ([@R22]). However, further studies will be required in order to confirm the link between ulceration and LDH levels suggested by this analysis. In addition, high levels of angiopoietin-2 have been reported in multiple cancers, with a possible prognostic role ([@R7]), and are accompanied by upregulation of RAC signaling pathways ([@R13]). Thus, it is possible that elevated PHIP copy number can modulate angiopoietin levels in melanoma, in part through mitrochondrial dysfunction, NADPH oxidase induction, and increased generation of reactive oxygen species (which result in angiopoietin-2 activation). In conclusion, our studies support an important role for PHIP as a molecular marker of melanoma ulceration, metastasis and survival, and provide insights into the cellular pathways through which ulceration can develop.

Materials and methods {#S4}
=====================

Study population {#S5}
----------------

This study used a tissue microarray cohort that was previously described according to REMARK guidelines ([@R27]; [@R21]). The molecular prognostic factor analyses performed herein were approved by the appropriate ethics boards both at CPMC and UCSF.

Fluorescence *in situ* hybridization (FISH) {#S6}
-------------------------------------------

FISH was performed as previously described ([@R34]; [@R8]; [@R29]) using BAC clones RP11-767O1, RP11-484L10, RP11-217L13 and CTD-2297E14 to detect the *PHIP* locus and clones RP11-26M18 and RP11-136K2 to detect 6q11.1 and 6p11.1 respectively (February 2009 freeze of the UCSC Genome Browser, <http://genome.ucsc.edu>). BAC DNA's were prepared with the Large-Construct kit (Qiagen, Valencia, CA) and labeled by nick translation with Alexa Fluor 488 and 594 dUTP's (Life Technologies, Grand Island, NY) as described ([@R34]). The quality and mapping of all probes were verified by hybridization to normal metaphase spreads in combination with a commercially available centromeric probe for chromosome 6 (Open Biosystems, Lafayette, CO) before tissue analysis. Hybridization on TMA's was performed as described previously ([@R34]; [@R8]). Images were taken with a Zeiss Axio Imager Z2 controlled by AxioVision software. The FISH signals were assessed and counted manually from images with several Z stack layers acquired using a Zeiss Axio Image Z2 microscope controlled by AxioVision software (Zeiss, Jena,Germany). At least 30 nuclei from each case were evaluated, and the signals were interpreted according to guidelines described previously ([@R6]) and recorded as 1 through 5 or greater. Signals from BAC clones detecting 6q11.1 and 6p11.1 were interpreted as the centromeric signal for chromosome 6 and the count was used as control.

Cell culture studies {#S7}
--------------------

C8161.9 human melanoma cells stably expressing anti-*PHIP* shRNA and anti-*luciferase* (anti-*luc*) shRNA were generated and propagated as described ([@R29]). Lactate production and invasion into matrigel were assayed as reported ([@R29]). C8161.9 cells were treated with 10 mM methylpyruvate (Sigma, St. Louis, MO.) for 48 hours before the invasion assay. VEGF secretion was measured by using an ELISA kit following the manufacturer's instructions (DY293B, R&D Systems Inc, Minneapolis, MN). Western blotting was performed as described using antibodies targeting HIF1A (ab16066, Abcam, Minneapolis, MN), LDH5 (ab1015, Abcam) and GAPDH (MAB374, Millipore, Billerica, MA).

Immunofluorescence {#S8}
------------------

Groups of 6 nu/nu mice were inoculated subcutaneously with 1 million C8161.9 human melanoma cells expressing either control *luc* or anti-*PHIP* shRNA. On day 25, the mice were euthanized and the tumors were assessed for microvessel density based on CD31 positivity by immunofluorescence, which was performed using a rabbit anti-CD31 antibody (ab28364, Abcam) and a secondary antibody labeled with Alexa Fluor 594 (Life Technologies) as described previously ([@R19]). Mosaic images were acquired with 20X magnification at a fixed exposure with a Zeiss Axio Imager Z2 microscope controlled by AxioVision software. After automatically stitching the images, the number of CD31 positive objects and area were determined using ImageJ software. The number of CD31 positive vessels was quantitated and the microvessel density reported as the total CD31 count over the entire area of the tumor.

Statistical Analysis {#S9}
--------------------

Statistical methods used to assess the significance of various prognostic factors on melanoma outcome were previously described ([@R27]; [@R21]). The coding for clinical or pathological attributes was performed as described by the AJCC staging committee for melanoma ([@R4]). The correlation between PHIP copy number and immunohistochemical score was tested by regression analysis using Data Desk software. For both DMFS and DSS, the definition of high *PHIP* FISH scores, as measured by percentage of cells harboring 3 or more copies of *PHIP*, was established as equal to or greater than 16%. A 16% cutoff served to maximize the average of the sensitivity and specificity in the prediction of both DMFS and DSS, analyzed separately. The same 16% cutoff was then uniformly and consistently used in all subsequent analyses of DMFS and DSS. The association between high *PHIP* copy number and DMFS or DSS was assessed using both Kaplan-Meier analysis and multivariate Cox regression. The association between high *PHIP* copy number and presence or absence of ulceration was assessed using both Fisher's exact test and multivariate logistic regression analysis. The association between a high degree of tumor vascularity and ulceration was also assessed using both Fisher's exact test and multivariate logistic regression. Assessment of the differential impacts of neither, either, and both of these two factors was done using both Chi-square analysis and Fisher's exact test. In predicting ulceration status, high *PHIP* copy number was uniformly defined as greater than or equal to 35% of tumor cells harboring 3 or more copies of the *PHIP* gene. This cutoff was similarly selected as the one that maximized the average of sensitivity and specificity in predicting ulceration. All *P* values reported are two-sided.

Supplementary Material {#SM}
======================

###### 

**Supplementary Figure 1**. Dot plot presenting the significant correlation between the immunohistochemical score and the percentage of cells with three or more copies of the *PHIP* locus in primary melanoma (P \< 0.0001, linear regression analysis).

**Supplementary Table 1**. FISH results as counts of signals from BAC clones mapping the PHIP locus and the flanking centromeric region of chromosome 6
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![*PHIP* copy number and its correlation with DMFS and DSS in melanoma patients. (a) Dual color FISH for *PHIP* locus, red, and centromere of chromosome 6, green, representative of low *PHIP* copy number, left panel, and high copy number, right panel. Scale bar = 20 Rm. (b) Kaplan-Meier analysis of DMFS in patients with low *PHIP* copy number (curve 1) *versus* patients with high *PHIP* copy number (curve 2). (c) Kaplan-Meier analysis of DSS in patients with low *PHIP* copy number (curve 1) *versus* patients with high *PHIP* copy number (curve 2).](nihms-520227-f0001){#F1}

![Effects of shRNA-mediated suppression of PHIP in human melanoma cells. (a) Lactate production in C8161.9 cells expressing anti-*PHIP* shRNA *versus* control cells expressing anti-*luc* shRNA. Mean ± SE; N = 3. \* denotes *P* \< 0.003. (b) Western analysis of LDH5 and HIF1A in C8161.9 cells expressing anti-*luc* shRNA (control cells, lane 1) or anti-*PHIP* shRNA (lane 2). (c) Invasive capacity of C8161.9 stable transformants expressing anti-*PHIP* shRNA with or without the addition of methylpyruvate (MP). Mean ± SE; N = 3. \* denotes *P* \< 0.05. (d) ELISA assay of human VEGF levels produced by C8161.9 cells expressing anti-*PHIP* shRNA *versus* control cells expressing anti-*luc* shRNA. Mean ± SE; N = 3. \* denotes *P* \< 0.0001.](nihms-520227-f0002){#F2}

![Effects of PHIP expression on the angiogenic potential of C8161.9 human melanoma cells *in vivo*. (a) Representative images of H&E staining of subcutaneous tumors in nude mice. The left panel shows the growth pattern of C8161.9 cells expressing anti-*luc* shRNA, compared with C8161.9 cells expressing anti-*PHIP* shRNA (right panel). (b) Composite images of immunofluorescence detection of CD31, red, and DAPI, blue as counterstain. The left panel shows the staining pattern of CD31 in subcutaneous tumor with C8161.9 cells expressing anti-*luc* shRNA compared with C8161.9 cells expressing anti-*PHIP* shRNA (right panel). Scale bar = 100 Rm. (c) Composite images of CD31 staining pattern with higher magnification for tumors with C8161.9 cells expressing anti-*luc* shRNA (left panel), or anti-*PHIP* shRNA (right panel). Scale bar = 20 Rm. (d) Quantification of microvessel density (MVD) based on CD31 immunofluorescence positivity in tumors (six per group) with C8161.9 cells expressing either anti-*luc* shRNA or anti-*PHIP* shRNA. Mean ± SD. \* denotes *P* \< 0.02.](nihms-520227-f0003){#F3}

###### 

Cox regression analysis of impact of various prognostic factors on DMFS of melanoma cohort (N = 231).

  [Prognostic factor]{.ul}   [Chi-square]{.ul}   [Risk Ratio]{.ul}   [P value]{.ul}
  -------------------------- ------------------- ------------------- ----------------
  Tumor thickness            6.96                1.38                .008
  High *PHIP* copy number    4.73                1.99                .03
  Ulceration                 3.31                1.51                .07
  Sex                        1.41                1.34                .24
  Site                       0.92                1.24                .34
  Age                        0.61                0.95                .44

###### 

Cox regression analysis of impact of various prognostic factors on DSS of melanoma cohort (N = 231).

  [Prognostic factor]{.ul}   [Chi-square]{.ul}   [Risk Ratio]{.ul}   [P value]{.ul}
  -------------------------- ------------------- ------------------- ----------------
  Tumor thickness            6.13                1.38                .013
  High *PHIP* copy number    4.87                2.21                .027
  Ulceration                 3.63                1.58                .057
  Sex                        1.00                1.30                .32
  Site                       0.81                1.24                .37
  Age                        0.01                0.99                .91

###### 

Logistic regression analysis of impact of various prognostic factors on incidence of ulceration in melanoma cohort (N = 228).

  [Prognostic factor]{.ul}   [Chi-square]{.ul}   [Odds Ratio]{.ul}   [P value]{.ul}
  -------------------------- ------------------- ------------------- ----------------
  Mitotic rate               15.24               1.23                .0001
  Tumor vascularity          10.26               3.05                .001
  Tumor thickness            5.99                1.63                .01
  High *PHIP* copy number    4.10                1.96                .04
